AzTrials
AzTrials

Non-Nutritive SweetenerNCT07434544

Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)

A study testing Cherry Sports Drink in people with Non-Nutritive Sweetener and Type 1 Diabetes, run by Medical College of Wisconsin at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes. Read more about this study

Who is it for?
Ages 15 to 24 years
What is being tested?
Cherry Sports Drink
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
5 Aug 2026to 31 Dec 2029
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 24 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Aged 15-24 years
  • Clinical diagnosis of type 1 diabetes, requiring insulin therapy, of ≥ 1 to < 10 years duration.
  • Last available HbA1c ≤ 8.5% (obtained by chart review in Children's Wisconsin Diabetes Clinic patients or verbally by individuals not receiving diabetes care at Children's Wisconsin)
  • Current use of an FDA approved automated insulin delivery (AID) system
  • Willing to consume a 12 ounce Gatorade G Zero Glacier Cherry drink in less than 10 minutes
  • Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is < 18 years of age

Who cannot join

  • Any disease other than type 1 diabetes that affects glucose, sex steroid, or fat metabolism such as polycystic ovary syndrome or hypercortisolism
  • Any medication use that may affect glucose, sex steroid, or fat metabolism such as metformin or glucocorticoids
  • Half or full sibling already participating in this study
  • Known cardiovascular disease such as hypertension or atherosclerosis, and/or use of an anti-hypertensive medication
  • Known hyperlipidemia, defined as LDL ≥ 160 mg/dL, and/or use of lipid-lowering medication, such as statin therapy
  • Known renal disease or microalbuminuria, and/or use of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARBs) for microalbuminuria
Show all 11Show fewer
  • Known diabetic retinopathy or neuropathy
  • Raynaud's phenomenon or other vascular disease
  • Obesity and/or body habitus that precludes completion of the flow-mediated brachial ultrasound study (generally, BMI > 40 kg/m2 in adults) - this is at study team's discretion.
  • Pregnancy or lactation
  • Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Susanne M Cabrera, MD contact

414-955-4903

T1dinfo@mcw.edu

United States1 site, 1 recruiting
  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226

    Susanne M Cabrera, MD

    Recruiting

Other trials in United States

About this study

Official title: The Cardiometabolic Impact of Non-Nutritive Sweeteners in Young Adults With Type 1 Diabetes

This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes.

Read the detailed description

The purpose of this project is to learn how NNS affects the health of the blood vessels.

Type 1 diabetes (T1D) is an autoimmune disease that requires lifelong dependence on prescribed insulin. Scientists know that if an individual has T1D, they are at greater risk of having cardiovascular disease than people who do not have diabetes.

To help manage diabetes, individuals may talk with their doctor about adjusting what they normally eat or drink. Doctors typically ask that individuals avoid foods and drinks with lots of sugar in them. In response to this, individuals might drink diet drinks or eat snacks or other foods that are sugar-free. Sugar-free drinks and foods have NNS which help things taste sweet without impacting their blood glucose.

Concern exists that consuming NNS may make individuals more at risk for developing cardiovascular disease. Although the American Heart Association advises against long-term NNS consumption, about 20% of all beverages consumed by children contain NNS.

Currently, there are no scientifically backed questionnaires to assess how much NNS someone is consuming. As well, there are no commercially available lab tests to determine how much NNS is in someone's blood. This makes it difficult to draw associations or causal relationships between NNS exposure and health outcomes.

By conducting this project, the investigators hope to gain knowledge to potentially inform and revise care guidelines for individuals with T1D and ultimately lead to improved nutritional recommendations and clinical care of children.

Being tested
Cherry Sports Drink
Keywords
Non-Nutritive Sweeteners, Type 1 Diabetes, Cardiometabolic, Long standing
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cherry Sports DrinkDietary supplement

    Also called Gatorade Zero Glacier Cherry™

    12 oz bottle (1 1/2 cups) of Gatorade G Zero Glacier Cherry™ Sports Drink

Study groups in NCT07434544
Study groupRoleWhat they receive
Treatment GroupExperimentalSports Drink - Participants will drink a cherry sports drink within 10 minutes.
Receives: Dietary Supplement: Cherry Sports Drink

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in "in vivo" endothelial function and vascular stiffness

    Brachial artery ultrasound will measure flow-mediated dilation % (FMD%) at baseline and 1 hour after drinking a non-nutritive sweetened sports drink.

    Measured: 2 years (duration of study)

Secondary outcomes (4)
  1. Associations of circulating NNS levels with self-reported food frequency assessments

    A food frequency survey has been developed of the most common categories of NNS containing foods and beverages. Participants will complete the food frequency survey to select the frequency by which they consumed a given product and the most common serving size over the past month.

    Measured: 2 years (duration of study)

  2. Impact of chronic NNS dietary consumption on cardiovascular health

    Changes 1-hour after NNS consumption from baseline will be measured by carotid-femoral pulse wave velocity, baseline flow velocity, and hyperemic flow velocity

    Measured: 2 years (duration of study)

  3. Impact of chronic NNS dietary consumption on metabolic health

    Changes 1-hour after NNS consumption from baseline will be measured by blood lipids, blood glucose, and blood pressure

    Measured: 2 years (duration of study)

  4. Impact of chronic NNS dietary consumption of T1D specific glycemic control

    Changes 1-hour after NNS consumption from baseline will be measured by 14-day continuous glucose monitor (CGM) data and 14-day insulin data for total daily dose and % basal insulin

    Measured: 2 years (duration of study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2026
  2. Study start5 Aug 2026
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion31 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Model description
Single-arm pre-post study
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07434544
Sponsor's protocol ID
PRO00057293
Status last verified
Oct 2026
First submitted
27 Jan 2026
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in